Drug intelligence / Profile preview

LASW-1835

Development stage: Unknown
Lead developer: Almirall
Modality: Small Molecules
Administration: Oral

Overview

LASW-1835 is an investigational oral small molecule drug developed for the treatment of moderate to severe chronic plaque psoriasis. It acts as a potent antagonist of the neurokinin 1 receptor, which is implicated in inflammatory pathways relevant to psoriasis. The drug was under development by Almirall and has been evaluated in clinical trials for its efficacy and safety compared to existing therapies[1][7].

Targets

TACR1 (Neurokinin‑1 Receptor)

Beyond the preview

Go deeper on LASW-1835.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LASW-1835.

Explore the full profile